May 29, 2024

Progression of Amyotrophic Lateral Sclerosis (ALS) Linked to Disruption of Mitochondria-Associated Membranes (MAM)

A recent study conducted by researchers at Nagoya University in Japan has identified a connection between the progression of Amyotrophic Lateral Sclerosis (ALS) and the disruption of mitochondria-associated membranes (MAM). These membranes serve as a contact point between the mitochondria and the endoplasmic reticulum (ER) within cells. The findings, published in the Proceedings of the National Academy of Sciences, shed light on the mechanisms involved in this neurodegenerative disease.

ALS is a complex condition that impacts motor neurons. Previous research has indicated that both mitochondria, which are responsible for cellular energy production, and the ER, a membrane network involved in protein synthesis, metabolism, and calcium storage, play a role in the development of the disease. The MAM, specifically where the ER and mitochondria interact, is believed to be of particular importance. However, the exact nature of this relationship remained unclear.

One potential factor in the progression of ALS is the enzyme TANK-binding kinase 1 (TBK1). TBK1 is involved in a range of biological processes, including inflammation and the removal of damaged proteins from cells. Dysfunction of TBK1 has been implicated in various diseases. While mutations in the TBK1 gene are known to cause ALS, the precise mechanism by which TBK1 malfunctions lead to disease development has yet to be fully understood.

The research team, led by Koji Yamanaka at Nagoya University’s Research Institute of Environmental Medicine and in collaboration with Masahisa Katsuno of the Graduate School of Medicine, investigated the activation levels of TBK1 in brain and spinal cord tissues from ALS patients, as well as in mice with disrupted MAM. The findings revealed reduced TBK1 activation in these samples.

Seiji Watanabe, the first author of the study, explains that TBK1 is essential for stress responses in motor neurons. Reduced TBK1 activity diminishes the neurons’ tolerance to stressors, leading to neurotoxicity and eventual motor neuron death. This discovery is particularly significant as abnormal protein accumulation and subsequent stress are known to contribute to ALS and other neurodegenerative diseases.

Furthermore, the researchers administered arsenite, a substance that lowers TBK1 activity and disrupts MAM, to mice. The mice exhibited motor problems similar to those seen in ALS patients. These findings strongly suggest that MAM plays a significant role in the stress response of motor neurons through the activation of TBK1. In line with previous genetic studies implicating TBK1 mutations in ALS, these findings suggest that restoring TBK1 activity could be a potential therapeutic strategy for treating ALS.

By focusing on the TBK1 pathway, the researchers have laid a critical foundation for developing new approaches to treat ALS and potentially other brain disorders. Lead researcher Yamanaka states that these results are expected to contribute to the development of novel therapeutic strategies for ALS in the future. Restoring TBK1 activity may emerge as an effective treatment approach for ALS. Further research in this area is underway, providing exciting prospects for future ALS treatments.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it